Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
about
Are oncoantigens suitable targets for anti-tumour therapy?Vaccines for tumour preventionInterleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cellsAn adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialStrategies to use immune modulators in therapeutic vaccines against cancerCryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.Immune surveillance of tumors.Optimizing dendritic cell-based approaches for cancer immunotherapyImmunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.Targeting Dendritic Cells in vivo for Cancer Therapy.DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice.Tumor antigen-based immunotherapy and immunoprevention of cancer.Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancerReengineering dendritic cell-based anti-cancer vaccines.Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans.In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.Camouflage and sabotage: tumor escape from the immune system.An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel.Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas.2011: the immune hallmarks of cancer.Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model.Cancer vaccine strategies: translation from mice to human clinical trials.Circumvention of regulatory CD4(+) T cell activity during cross-priming strongly enhances T cell-mediated immunity.Foxo transcription factors in T cell biology and tumor immunity.Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.
P2860
Q28240977-E62BCE2B-ABA0-4575-B5CD-E50DE34A930DQ28299036-5D6B3736-862F-431D-8D56-EE4EA8977E5CQ33638464-552FC2EE-FBC1-49D9-AA30-4C6AD42E7BE7Q33645792-BB385924-D212-4853-945F-2A8524FDA55EQ33699124-7CC1EB01-DB03-4DDA-8EF6-852B3D7205F3Q33991804-D816A534-C89F-4474-8989-226F7C794E21Q34275601-9BAFB16E-DCBD-4E74-A7E2-AD446BAFB468Q34288183-2A1D6C21-3477-42CD-9F21-9DB9C5E85A10Q34579196-DB24E471-3116-4303-87A7-B7BF33600982Q34637535-A6457412-971B-4A79-8670-20F8A90B109AQ35201826-14EEA461-D470-427F-8B00-4841E84D0075Q35710332-1545A814-B358-492E-B917-5BA1944CF7A4Q35838039-96277B4E-0853-4F4B-B754-63C99C4C98E1Q35928270-E7DFFA4D-CB17-451E-B4A7-250ACA99729AQ36411564-094B694F-3CF2-450F-B144-D91499DD4675Q36654072-91722B5C-B200-4D5B-ABF0-AB6116F625C6Q36659250-15E7E3FC-C334-422E-8EFD-721FE4658C18Q36821263-D30F3C82-34AC-48DF-96FF-11369795806CQ37118177-8869EBD5-AECC-4BB5-B16A-18AA853199E3Q37137404-47320752-9691-444A-BA4C-06E7F514161BQ37220754-A0C7D437-4C13-47E4-9E02-B595F656A617Q37412304-FC2A8B7C-F442-487E-9D84-E102E53B4F2FQ37727967-84DDFB15-70E2-4151-8A77-B4F1CBB0247AQ37882478-8512D1A7-955E-4B56-B837-C444223E60C3Q39920448-C6AFF0A7-A7C9-4F96-A094-82A2591DD827Q40035245-1F9CE7B3-933C-4814-82CC-B6C4950131B4Q40209925-156FD8E8-393B-4601-AB5F-B996A6145C60Q40375544-49426701-AFA1-49BA-8F76-E6775ACD0C96Q42217850-89A55C3F-CAF1-4B40-A94E-5753F8857F2BQ45869351-894C2D13-5208-4C91-9817-358A73017510Q48295639-50A9FE73-07FB-44DC-8D2B-7C94A44CD0C7Q51964906-08560784-4E80-49FF-890F-026DAB6554BEQ52569779-2225B024-1DA3-40A4-8009-03369D43ABAFQ53248364-D4354985-425D-4248-A197-EA4949C1A47E
P2860
Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Early role of CD4+ Th1 cells a ...... ochthonous mammary carcinomas.
@en
Early role of CD4+ Th1 cells a ...... ochthonous mammary carcinomas.
@nl
type
label
Early role of CD4+ Th1 cells a ...... ochthonous mammary carcinomas.
@en
Early role of CD4+ Th1 cells a ...... ochthonous mammary carcinomas.
@nl
prefLabel
Early role of CD4+ Th1 cells a ...... ochthonous mammary carcinomas.
@en
Early role of CD4+ Th1 cells a ...... ochthonous mammary carcinomas.
@nl
P2093
P1476
Early role of CD4+ Th1 cells a ...... ochthonous mammary carcinomas.
@en
P2093
Guido Forni
Jay A Berzofsky
Jeeva Munasinghe
John C Morris
Jong Myun Park
Masaki Terabe
Yoshio Sakai
P304
P356
10.4049/JIMMUNOL.174.7.4228
P407
P577
2005-04-01T00:00:00Z